药盒埋置持续性动脉灌注化疗治疗中晚期胰腺癌的临床研究  

Clinical Study on Port-catheter System Implantation Transcatheter Arterial Infusion in Treating Advanced Pancreatic Carcinoma

作　　者：周泽健[1] 邵培坚[1] 李伟科[1] 许荣德[1] 庄文行[1] 罗鹏飞[1] 

机构地区：[1]广东省人民医院肿瘤中心介入治疗科,广州510080

出　　处：《肿瘤防治研究》2004年第12期779-781,共3页Cancer Research on Prevention and Treatment

摘　　要：目的　评价药盒埋置持续性动脉灌注化疗治疗中晚期胰腺癌的临床效果。方法　采用左锁骨下动脉药盒埋置持续性动脉灌注化疗治疗的 2 5例胰腺癌患者为介入治疗组 ,同期接受全身化疗的 2 8例胰腺癌患者为全身化疗组 ,两组均给予健择 +5 氟尿嘧啶方案 ,比较两组临床受益反应、肿瘤大小变化、患者生存情况以及毒副反应。结果　介入治疗组和全身化疗组临床受益率分别为 5 2 .0 %和 2 1.4 %(P <0 .0 5 ) ;总有效率 (CR +PR)分别为 16 .0 %和 10 .7% (P >0 .0 5 ) ;中位生存时间分别为 8.1个月和 6 .8个月 (P >0 .0 5 ) ,半年累积生存率分别为 79.4 %和 5 2 .3% (P <0 .0 5 ) ;1年累积生存率分别为 35 .7%和31.5 % (P >0 .0 5 )。毒副反应以胃肠道反应为主 ,无Ⅲ度以上的血液学、胃肠道及肝肾功能的毒副反应。结论　药盒埋置持续性动脉灌注化疗可以提高中晚期胰腺癌的临床受益率和短期生存率。Objective To evaluate the clinical value of port-catheter system implantation transcatheter arterial infusion in treating advanced pancreatic carcinoma. Methods 25 patients with advanced pancreatic carcinoma received interventional treatment(Intervention group) while 28 patients received systemic chemotherapy(Systemic chemotherapy group). Gemcitabine and 5-Fu were given to all patients. Results Clinical benefit response(CBR) in intervention group and systemic chemotherapy group were 52.0% and 21.4% respectively (P< 0.05); tumor response rate (CR+PR) were 16.0% and 10.7%(P> 0.05); median survival time were 8.1 and 6.8 months (P> 0.05); half-year survival rate were 79.4% and 52.3% (P< 0.05); 1-year survival rate were 35.7% and 31.5% (P> 0.05). No severe side-effect was found in both two groups. Conclusion The port-catheter system implantation transcatheter arterial infusion can improve CBR and half-year survival rate.

关 键 词：胰腺癌 导管-药盒系统 灌注化疗 持续性 

分 类 号：R730.53[医药卫生—肿瘤] R735.9[医药卫生—临床医学]